Last reviewed · How we verify
MSD Pharmaceuticals LLC — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Antiretroviral/Anti HIV | Antiretroviral/Anti HIV | marketed | Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor) | HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent) | Infectious Disease / Virology | |
| Golimumab Injection | Golimumab Injection | phase 3 | TNF-α inhibitor (monoclonal antibody) | TNF-α | Immunology |
Therapeutic area mix
- Immunology · 1
- Infectious Disease / Virology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
- Biocad · 1 shared drug class
- Celltrion · 1 shared drug class
- Centocor, Inc. · 1 shared drug class
- Children's Memorial Health Institute, Poland · 1 shared drug class
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 1 shared drug class
- Hanyang University Seoul Hospital · 1 shared drug class
- AbbVie (prior sponsor, Abbott) · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for MSD Pharmaceuticals LLC:
- MSD Pharmaceuticals LLC pipeline updates — RSS
- MSD Pharmaceuticals LLC pipeline updates — Atom
- MSD Pharmaceuticals LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). MSD Pharmaceuticals LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/msd-pharmaceuticals-llc. Accessed 2026-06-10.